These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25126372)

  • 1. The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis.
    Fitch K; Broulette J; Kwong WJ
    Am Health Drug Benefits; 2014 Jun; 7(4):200-9. PubMed ID: 25126372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation.
    Fitch K; Broulette J; Pyenson B; Iwasaki K; Kwong WJ
    Am Health Drug Benefits; 2012 May; 5(3):157-68. PubMed ID: 24991318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
    Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
    Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
    Kaatz S; Coleman CI; Bookhart B; Laliberté F; Nelson WW; Brown K; Martin S; Schein J; Lefebvre P
    Curr Med Res Opin; 2018 Feb; 34(2):275-284. PubMed ID: 29164990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model.
    Sussman M; Di Fusco M; Tao CY; Guo JD; Gillespie JA; Ferri M; Adair N; Cato MS; Shirkhorshidian I; Barnes GD
    J Med Econ; 2021; 24(1):1070-1082. PubMed ID: 34415229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
    Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
    Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
    Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
    J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands.
    Chen Q; Toorop MMA; Tops LF; Lijfering WM; Cannegieter SC
    JAMA Netw Open; 2023 Apr; 6(4):e239973. PubMed ID: 37097630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
    Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
    Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry.
    Shiozawa M; Koga M; Inoue H; Yamashita T; Yasaka M; Suzuki S; Akao M; Atarashi H; Ikeda T; Okumura K; Koretsune Y; Shimizu W; Tsutsui H; Hirayama A; Nakahara J; Teramukai S; Kimura T; Morishima Y; Takita A; Yamaguchi T; Toyoda K
    Int J Stroke; 2023 Oct; 18(8):986-995. PubMed ID: 37154598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
    J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation.
    Mercaldi CJ; Siu K; Sander SD; Walker DR; Wu Y; Li Q; Wu N
    Cardiol Res Pract; 2012; 2012():645469. PubMed ID: 23082276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer.
    Deitelzweig S; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Lip GYH
    JACC CardioOncol; 2021 Sep; 3(3):411-424. PubMed ID: 34604802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator.
    Nguyen TN; Trocio J; Kowal S; Ferrufino CP; Munakata J; South D
    Am Health Drug Benefits; 2016 Dec; 9(9):475-485. PubMed ID: 28465775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.